Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bosulif bosutinib regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending against the use of Bosulif bosutinib from Pfizer to treat previously treated chronic, accelerated

Read the full 225 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE